Nisa Investment Advisors LLC Increases Stock Position in Cencora, Inc. $COR

Nisa Investment Advisors LLC lifted its position in shares of Cencora, Inc. (NYSE:COR) by 10.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,105 shares of the company’s stock after buying an additional 7,605 shares during the period. Nisa Investment Advisors LLC’s holdings in Cencora were worth $24,098,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC grew its position in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC lifted its holdings in shares of Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares in the last quarter. Caldwell Trust Co acquired a new stake in Cencora in the 2nd quarter valued at $46,000. Salomon & Ludwin LLC lifted its position in Cencora by 638.1% during the 3rd quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock worth $47,000 after acquiring an additional 134 shares in the last quarter. Finally, Capital A Wealth Management LLC lifted its position in shares of Cencora by 3,975.0% during the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock worth $49,000 after purchasing an additional 159 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 20,317 shares of company stock valued at $7,009,260. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $335.73 on Friday. Cencora, Inc. has a 52 week low of $233.61 and a 52 week high of $377.54. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The firm has a market cap of $65.13 billion, a price-to-earnings ratio of 42.23, a PEG ratio of 1.60 and a beta of 0.66. The stock has a 50 day moving average of $349.89 and a 200-day moving average of $318.10.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the business posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is 30.19%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on COR shares. Barclays initiated coverage on Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 price target on the stock. Bank of America cut their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. JPMorgan Chase & Co. increased their target price on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. Finally, Robert W. Baird set a $392.00 price target on shares of Cencora in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average target price of $379.50.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.